Pentamidine
Nebupent, Pentam (pentamidine) is a small molecule pharmaceutical. Pentamidine was first approved as Pentam on 1984-10-16. It is used to treat pneumocystis pneumonia, protozoan infections, trypanosomiasis, and visceral leishmaniasis in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Nebupent, Pentam (generic drugs available since 2017-09-28, discontinued: Pentacarinat)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| nebupent | New Drug Application | 2020-01-23 |
| pentamidine isethionate | ANDA | 2023-06-13 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pneumocystis pneumonia | EFO_0007448 | D011020 | B59 |
| protozoan infections | — | D011528 | B50-B64 |
| trypanosomiasis | DOID_10113 | D014352 | B57.2 |
| visceral leishmaniasis | — | D007898 | B55.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2545 | Pentamidine isethionate, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 300 mg |
| J7676 | Pentamidine isethionate, inhalation solution, compounded product, administered through dme, unit dose form, per 300 mg |
| S0080 | Injection, pentamidine isethionate, 300 mg |
| S9061 | Home administration of aerosolized drug therapy (e.g., pentamidine); administrative services, professional pharmacy services, care coordination, all necessary supplies and equipment (drugs and nursing visits coded separately), per diem |
Clinical
Clinical Trials
36 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 1 | 7 | — | 10 | 20 |
| Pneumocystis pneumonia | D011020 | EFO_0007448 | B59 | 2 | 1 | 7 | — | 10 | 20 |
| Cutaneous leishmaniasis | D016773 | B55.1 | — | 3 | 1 | — | — | 3 | |
| Leishmaniasis | D007896 | EFO_0005044 | B55 | — | 1 | 1 | — | — | 1 |
| Visceral leishmaniasis | D007898 | B55.0 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | 1 | 2 | — | — | — | 2 | ||
| Lymphoma | D008223 | C85.9 | — | 1 | — | — | — | 1 | |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 1 | — | — | — | 1 |
| Kidney transplantation | D016030 | 1 | 1 | — | — | — | 1 | ||
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | — | — | — | 1 |
| Hypertrophic cicatrix | D017439 | L91.0 | 1 | 1 | — | — | — | 1 | |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | — | — | — | 1 |
| African trypanosomiasis | D014353 | B56 | — | 1 | — | — | — | 1 | |
| Melanoma | D008545 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hodgkin disease | D006689 | C81 | 1 | — | — | — | — | 1 | |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic neoplasms | D019337 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PENTAMIDINE |
| INN | pentamidine |
| Description | Pentamidine is a diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease. It has a role as a trypanocidal drug, an antifungal agent, a NMDA receptor antagonist, an anti-inflammatory agent, a chemokine receptor 5 antagonist, an EC 2.3.1.48 (histone acetyltransferase) inhibitor, a calmodulin antagonist, a S100 calcium-binding protein B inhibitor and a xenobiotic. It is a carboxamidine, a diether and an aromatic ether. It is a conjugate base of a pentamidinium(2+). |
| Classification | Small molecule |
| Drug class | pentamidine derivatives/analogues |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 100-33-4 |
| RxCUI | 7994 |
| ChEMBL ID | CHEMBL55 |
| ChEBI ID | 45081 |
| PubChem CID | 4735 |
| DrugBank | DB00738 |
| UNII ID | 673LC5J4LQ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 99 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
565 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more